2020 Maryland Stem Cell Research Fund - RFA Available Now
The 2020 Request for Applications for Maryland
Stem Cell Research Fund (MSCRF) Discovery, Validation, Clinical,
Commercial and Post-Doctoral Fellowship programs are available for
now. New this year is the "Launch" grant, which is open to
new faculty or researchers of any rank who are new to the field of
stem cell research. Detailed eligibility information and guidelines
are available for download on MSCRF's website.
Applications are due Thursday, January 16, 2020 by 5:00 PM. ORA
must review and approve all applications before submission. If you plan
to submit an application or have questions about the submission process
please contact ORA Assistant Director of Grants Sharel Brown (email@example.com).
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.